Clinical Study

Effects of Low-Dose Testosterone Undecanoate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Male Osteoporosis with Low Serum Testosterone

Table 1

Characteristics of the patients at the entry (means ± SD).

ParameterABC

Regimen of treatmentTU 40 mg/dTU 20 mg/dPlacebo 1 tablet/d
Patients (no)626262
Age (yr)
Height (cm)
Weight (kg)
BMI (kg/m2)
SBP (mmHg)
DBP (mmHg)
FPG (mmol/L)
HbA1c (%)
TC (mmol/L)
TG (mmol/L)
HDL-CH (mmol/L)
LDL-CH (mmol/L)
PSA (ng/mL)
fPSA (ng/mL)
BMD (g/cm2)
 Lumbar spine
 Femoral neck
Sex hormones
 TT (ng/dL)
 fT (pg/mL)
 E2 (pg/mL)
Bone turnover markers
 BAP (IU/L)
 uNTX/Cr (nmol/mmol)

TU: testosterone undecanoate; BMI: body mass index; FPG: plasma glucose; HbA1c: glycosylated hemoglobin A1c; TC: total cholesterol; TG: triglyceride; HDL-CH: high-density lipoprotein cholesterol; LDL-CH: low-density lipoprotein cholesterol; PSA: prostate specific antigen; fPSA: free prostate specific antigen; BMD: bone mineral density; TT: total testosterone; fT: free testosterone; E2: estradiol; BAP: bone-specific alkaline phosphatase; uNTX/Cr: urine N-telopeptide of type 1 collagen/creatinine.